RPHM vs. CLNN, LTRN, IMMX, BLRX, EGRX, HCWB, CELU, EQ, ELDN, and JAGX
Should you be buying Reneo Pharmaceuticals stock or one of its competitors? The main competitors of Reneo Pharmaceuticals include Clene (CLNN), Lantern Pharma (LTRN), Immix Biopharma (IMMX), BioLineRx (BLRX), Eagle Pharmaceuticals (EGRX), HCW Biologics (HCWB), Celularity (CELU), Equillium (EQ), Eledon Pharmaceuticals (ELDN), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical preparations" industry.
Clene (NASDAQ:CLNN) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk.
In the previous week, Clene had 3 more articles in the media than Reneo Pharmaceuticals. MarketBeat recorded 8 mentions for Clene and 5 mentions for Reneo Pharmaceuticals. Clene's average media sentiment score of 0.90 beat Reneo Pharmaceuticals' score of -0.16 indicating that Reneo Pharmaceuticals is being referred to more favorably in the news media.
Clene has higher revenue and earnings than Reneo Pharmaceuticals. Clene is trading at a lower price-to-earnings ratio than Reneo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Clene currently has a consensus price target of $6.50, indicating a potential upside of 1,545.57%. Reneo Pharmaceuticals has a consensus price target of $18.14, indicating a potential upside of 875.13%. Given Reneo Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Clene is more favorable than Reneo Pharmaceuticals.
Clene has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Reneo Pharmaceuticals has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.
Clene received 38 more outperform votes than Reneo Pharmaceuticals when rated by MarketBeat users. Likewise, 75.32% of users gave Clene an outperform vote while only 58.82% of users gave Reneo Pharmaceuticals an outperform vote.
23.3% of Clene shares are held by institutional investors. Comparatively, 91.0% of Reneo Pharmaceuticals shares are held by institutional investors. 25.1% of Clene shares are held by insiders. Comparatively, 17.9% of Reneo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Reneo Pharmaceuticals has a net margin of 0.00% compared to Reneo Pharmaceuticals' net margin of -7,569.42%. Clene's return on equity of -73.14% beat Reneo Pharmaceuticals' return on equity.
Summary
Clene beats Reneo Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Reneo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPHM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPHM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reneo Pharmaceuticals Competitors List
Related Companies and Tools
